Evidence map›Paper›PMID 25883991›Full record

ArticleJournal of immunology research2015

Immunodiagnostic significance of anti-RA33 autoantibodies in Saudi patients with rheumatoid arthritis.

Jamil A Al-Mughales

Open access · goldAbstract read
In one paragraph

Article in Journal of immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Anti-RA33 Antibodies Are Present in Patients With Lyme Disease.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2025
    Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Jamil A Al-MughalesDepartment of Clinical Laboratory Medicine (Diagnostic Immunology Division) and Department of Medical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, P.O. Box 80215, Jeddah 21519, Saudi Arabia.
King Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledThe primary objective of this study was to evaluate and compare the immunodiagnostic significance and utility of anti-RA33 with anti-CCP, RF, and CRP in Saudi patients with rheumatoid arthritis.

methodsThis was a prospective controlled clinical study conducted at King Abdul Aziz University Tertiary Medical Centre. The sera of 41 RA patients, 31 non-RA patients, and 29 healthy controls were collected. Anti-RA33 and anti-CCP were measured using commercially available ELISA principle kits. RF and CRP were measured using nephelometry.

resultsAnti-RA33 antibodies had the lowest positive and negative predictive values and showed a sensitivity of 7.32% with 95.12% specificity. Of the other three markers (including anti-CCP antibodies, CRP, and RF), only anti-CCP showed specificity of 90.46% with sensitivity of 63.41% compared to non-RA patients + healthy control. There was a significant correlation with rheumatoid factor positivity with anti-CCP. With respect to CRP, a notable correlation was seen only with anti-RA33.

conclusionCompared to rheumatoid factor, anti-CCP antibodies, and C-reactive proteins, the anti-RA33 autoantibodies seem to be not representing as an important additional immunodiagnostic marker in Saudi patients with established RA. RA33 may have more interest in early RA or less severe RA and other systemic connective tissue disorders.

Indexed as

AdultAntibodies, AntinuclearArthritis, RheumatoidAutoantibodiesBiomarkersC-Reactive ProteinFemaleHeterogeneous-Nuclear Ribonucleoprotein Group A-BHumansImmunoglobulin GImmunologic TestsMaleMiddle AgedPeptides, CyclicRheumatoid FactorSaudi ArabiaAntibodies, AntinuclearAutoantibodiesBiomarkersC-Reactive Proteincyclic citrullinated peptideHeterogeneous-Nuclear Ribonucleoprotein Group A-BImmunoglobulin GPeptides, CyclicRheumatoid Factor

Identifiers

PMID25883991
PMCPMC4389979
OpenAlexW2073999129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.